共 143 条
[1]
Spasovski G(2014)Clinical practice guideline on diagnosis and treatment of hyponatraemia Eur J Endocrinol 170 G1-47
[2]
Vanholder R(1985)Hyponatremia: a prospective analysis of its epidemiology and the pathogenetic role of vasopressin Ann Intern Med 102 164-8
[3]
Allolio B(2011)Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion Eur J Endocrinol Suppl 164 725-32
[4]
Annane D(2006)Salt Investigators: Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia N Engl J Med 355 2099-112
[5]
Ball S(2007)New agents for managing hyponatremia in hospitalized patients Am J Health Syst Pharm 64 253-65
[6]
Bichet D(2014)Electrolyte disorders associated with cancer Adv Chronic Kidney Dis 21 7-17
[7]
Decaux G(1993)Atrial natriuretic factor and arginine vasopressin production in tumor cell lines from patients with lung cancer and their relationship to serum sodium Cancer Res 53 67-74
[8]
Fenske W(2015)Current treatment practice and outcomes. Report of the hyponatremia registry Kidney Int 88 167-77
[9]
Hoorn EJ(2012)Evaluation of costs associated with tolvaptan-mediated length-of-stay reduction among heart failure patients with hyponatremia in the US, based on the EVEREST trial J Med Econ 15 276-84
[10]
Ichai C(2012)Evaluation of costs associated with tolvaptan-mediated hospital length of stay reduction among US patients with the syndrome of inappropriate antidiuretic hormone secretion, based on SALT-1 and SALT-2 trials Hospital practice (1995) 40 7-14